Skip to main content
. 2020 Jun 15;10(8):1521–1533. doi: 10.1016/j.apsb.2020.06.005

Figure 6.

Fig. 6

Anti-AS activities in vivo. Artery lumen diameter determination. (A) H&E staining and (B) quantitative assay (mean ± SD, n = 5, ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001). The scale bar is 100 μm. Determinations of (C) systemic blood pressure, (D)–(F) inflammatory factors in aortas, and (G)–(I) serum lipid profile at the end of the treatment (mean ± SD, n = 5, ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001). The formulations (0.2 mL), saline, naked RNA, atorvastatin, BNRs, BNRplex, SA-BNRplex, were injected into the animals via the tail vein every 3 days at a baicalein dose of 5 mg/kg, anti-miR 155 dose of 0.2 mg/kg, or atorvastatin dose of 1 mg/kg, according to the body weight.